Hey ALDX is up 3.5% on decent volume for it.
Earnings tomorrow.
They won't have any but they'll have updates.
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
Earnings tomorrow.
They won't have any but they'll have updates.
Reproxalap: Our Novel Small Molecule Drug Candidate for Dry Eye
By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. We believe that reproxalap may have a commercially differentiated product profile versus currently approved drugs for each indication, having shown the potential for early and broad activity in dry eye disease. Additionally, reproxalap, if approved, has added the potential of being the only product that may be able to effectively treat dry eye disease, uniquely addressing the needs of the large underserved population that suffers from this disease. Topical ocular reproxalap has been studied in over 1,100 patients thus far with no observed safety concerns reported. Mild instillation site irritation is the most commonly reported adverse event in clinical trials.
Aldeyra intends to advance 0.25% topical ocular reproxalap, our lead RASP inhibitor, for the treatment of dry eye disease.
Clinical Results for Dry Eye Disease
In a Phase 2b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.
By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. We believe that reproxalap may have a commercially differentiated product profile versus currently approved drugs for each indication, having shown the potential for early and broad activity in dry eye disease. Additionally, reproxalap, if approved, has added the potential of being the only product that may be able to effectively treat dry eye disease, uniquely addressing the needs of the large underserved population that suffers from this disease. Topical ocular reproxalap has been studied in over 1,100 patients thus far with no observed safety concerns reported. Mild instillation site irritation is the most commonly reported adverse event in clinical trials.
Aldeyra intends to advance 0.25% topical ocular reproxalap, our lead RASP inhibitor, for the treatment of dry eye disease.
Clinical Results for Dry Eye Disease
In a Phase 2b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.
Van push come to shove I would say tomorrow starts something bad. You can feel the card sharps out there destroying things.
Snap Inc. (SNAP)- $51.50 low- $55 high.....
NYSE - Nasdaq Real Time Price. Currency in USD
52.70-2.69 (-4.87%)
As of 12:40PM EDT. Market open.
NYSE - Nasdaq Real Time Price. Currency in USD
52.70-2.69 (-4.87%)
As of 12:40PM EDT. Market open.
I'm afraid to even look Van they took eye companies out last week 3 failed! It's just fucking dry eye for god sake but of course the eyes are very delicate. The odds are probably in your favor at this point.
You know the market sucks when the best move you pull off is selling something before it falls.
eBay Inc. (EBAY)-
77.48-1.02 (-1.30%)
As of 12:56PM EDT.
eBay Inc. (EBAY)-
77.48-1.02 (-1.30%)
As of 12:56PM EDT.
Like I said, ignore the noise.
Buy the dip.
Ebay will be just fine.
Quarterly earnings..... whatever.
Apparently dry eye disease is a big deal. That's why you went in on OCUL right?
This ALDX company, they're definitely for real.
Aren't they the ones building the huge facility in PA?
For making this stuff?
Last edited: